Sidley represented ADARx Pharmaceuticals, Inc. on the deal. ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, announced its US$46 million Series B-1 financing. The proceeds...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here